
WB analysis of various sample lysates using GTX64548 Interferon gamma Receptor 2 antibody. The signal was developed with ECL plus-Enhanced. Dilution : 1:1000 Loading : 25microg per lane
Interferon gamma Receptor 2 antibody
GTX64548
ApplicationsWestern Blot
Product group Antibodies
TargetIFNGR2
Overview
- SupplierGeneTex
- Product NameInterferon gamma Receptor 2 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500 - 1:2000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot
- CertificationResearch Use Only
- ClonalityPolyclonal
- ConjugateUnconjugated
- Gene ID3460
- Target nameIFNGR2
- Target descriptioninterferon gamma receptor 2
- Target synonymsAF-1, IFGR2, IFNGT1, IMD28, interferon gamma receptor 2, IFN-gamma receptor 2, IFN-gamma-R-beta, IFN-gamma-R2, interferon gamma receptor accessory factor-1, interferon gamma receptor beta chain, interferon gamma transducer 1
- HostRabbit
- IsotypeIgG
- Protein IDP38484
- Protein NameInterferon gamma receptor 2
- Scientific DescriptionThis gene (IFNGR2) encodes the non-ligand-binding beta chain of the gamma interferon receptor. Human interferon-gamma receptor is a heterodimer of IFNGR1 and IFNGR2. Defects in IFNGR2 are a cause of mendelian susceptibility to mycobacterial disease (MSMD), also known as familial disseminated atypical mycobacterial infection. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance. [provided by RefSeq, Jul 2008]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Liu XD, Kong W, Peterson CB, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020,11(1):2135. doi: 10.1038/s41467-020-15959-6Read this paper
- Ingram JP, Tursi S, Zhang T, et al. A Nonpyroptotic IFN-γ-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol. 2018,200(10):3626-3634. doi: 10.4049/jimmunol.1701386Read this paper





